ClinicalTrials.gg
Not yet recruitingNCT07377097SweetheartUpdated Jan 29, 2026

Effects of Sweetener Consumption on Risk Factors for Heart Disease in Prediabetic Subjects

An interventional study of Saccharin and Sucralose in Prediabetic State, Metabolic Syndrome and Insulin Resistance, sponsored by Charite University, Berlin, Germany. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by Charite University, Berlin, Germany · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The aim of this prospective interventional study is to investigate the metabolic effects of consuming artificial and natural sweeteners in persons with prediabetes. Prediabetes is a condition characterized by blood sugar levels that are elevated above normal but not yet meeting the criteria for type 2 diabetes. This condition markedly increases the risk of progressing to type 2 diabetes, which in turn can lead to complications including cardiovascular diseases.

Artificial sweeteners such as saccharin and sucralose, as well as natural sugar substitutes like erythritol, are increasingly used as alternatives to sugar and are recommended for individuals at cardiometabolic risk - including overweight individuals, patients with prediabetes, or diabetics - to help reduce caloric intake. Recent literature has reported possible negative associations between artificial sweeteners and blood sugar regulation in healthy subjects (1). Additionally, effects on various blood cells have been observed. For example, erythritol has been shown to alter platelet function leading to increased reactivity in healthy study participants following consumption (2).

However, the impact of alternative sweeteners on metabolic processes and their effects on blood coagulation in patients with prediabetes-a population at increased risk-has not been systematically studied. In this planned interventional study, 80 patients meeting laboratory criteria for prediabetes will be randomly assigned to one of four groups, each receiving a different intervention for two weeks: saccharin, sucralose, erythritol, or a control group receiving water. The doses reflect the acceptable daily intake or known doses that are considered safe.

After enrollment, participants will visit the study center 2 times: before starting the intervention and after completing the intervention. During these visits, biological samples such as blood, urine, and stool will be collected to study metabolism, gut bacteria, immune and blood cell function. Tests will include an oral glucose tolerance test, coagulation tests, and additional blood analyses. Additionally, participants will wear a glucose monitor to track blood sugar fluctuations during the intervention.

The investigators hypothesize that consumption of alternative sweeteners negatively affects blood sugar regulation and insulin sensitivity in patients with prediabetes. Furthermore, this study will explore how the candidate sweeteners influence the gut microbiome, blood cells and other metabolic factors in this population.

02

Conditions studied

  • Prediabetic State
  • Metabolic Syndrome
  • Insulin Resistance
  • Thrombosis
  • Hypercoagulable State
  • Cardiovascular (CV) Risk
  • Cardiovascular Risk Factors
  • Cardiovascular Diseases (CVD)
  • Prediabetes
  • Prediabetes / Type 2 Diabetes
  • Sweeteners
03

In context

Prediabetic State

919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.

This study's planned enrollment of 80 is above the median of 62 across 763 interventional studies indexed under Prediabetic State.

Browse Prediabetic State studies →

Lead sponsor

Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 128 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presence of prediabetes ( 5.7-6.4% or glucose after oral glucose tolerance test 140 to 199 mg/dL)
  • Written available

Exclusion criteria

Exclusion Criteria:

  • Inability to communicate sufficiently in the required language
  • Dementia or other significantly cognitively impairing condition
  • Current pregnancy or breastfeeding
  • Other severe internal, neurological, or psychiatric condition
  • History of gout
  • History of gallstones / diagnosis of cholelithiasis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Saccharin Group

    Intervention: Saccharin

    Dietary Supplement: Saccharin

  • Active comparator
    Sucralose Group

    Intervention: Sucralose

    Dietary Supplement: Sucralose

  • Active comparator
    Erythritol Group

    Intervention: Erythritol

    Dietary Supplement: Erythritol

  • Placebo comparator
    Control Group

    Intervention: Vehicle

    Dietary Supplement: Vehicle

Interventions

  • Dietary supplementSaccharin

    Participants in the saccharin group will consume 5 mg/kg body weight of saccharin daily, dissolved in 500 mL of water. This corresponds to the maximum recommended daily intake as determined by EFSA and JECFA (the joint FAO/WHO Expert Committee on Food Additives).

  • Dietary supplementTrichlorosucroseStudies of TrichlorosucroseTrichlorosucrose pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants in the sucralose group will consume 15 mg/kg body weight of sucralose daily in 500 mL of water, representing the maximum recommended daily intake.

  • Dietary supplementErythritol

    Those in the erythritol group will consume 0.5 g/kg body weight of erythritol daily in 500 mL of water, a dose considered safe and below levels that cause digestive discomfort (European Food Safety Authority \[EFSA\], 2023).

  • Dietary supplementVehicle

    Participants in the control group (vehicle) will receive a vehicle consisting of 500 mL unsweetened lemon soda

06

What researchers measure

Primary outcomes

  1. Change of glucose tolerance

    Measured by AUC of oral glucose tolerance test

    Time frame: Baseline vs. within 1 week after intervention

Secondary outcomes

  1. Change of microbiome

    RNA-Sequencing of stool samples

    Time frame: Baseline vs. within 1 week after intervention

  2. Flow cytometry analysis of changes in frequency of circulating monocyte subsets (%)

    Measured by flow cytometry in isolated PBMCs (Peripheral Blood Mononuclear Cells) using specific antibodies with binding to CD45, CD14, CD15 and CD16 to define monocyte subsets. Values will be reported as percent of CD45+ leukocytes

    Time frame: Baseline vs. within 1 week after intervention

  3. Flow cytometry analysis of changes in platelet activation marker expression (% positive platelets)

    Whole blood samples will be analyzed using flow cytometry. Platelets will be detected based on size and using well-established surface markers (CD41). Activation markers will be assessed (CD62P and PAC1) and reported as percent of positive cells.

    Time frame: Baseline vs. within 1 week after intervention

  4. Flow cytometry analysis of changes in platelet activation marker expression (MFI)

    Whole blood samples will be analyzed using flow cytometry. Platelets will be detected based on size and using well-established surface markers (CD41). Activation markers will be assessed (CD62P and PAC1) and reported as mean fluorescence intensity.

    Time frame: Baseline vs. within 1 week after intervention

  5. Changes in lipid profile

    Serum analysis of Total cholesterol, HDL and LDL cholesterol, triglycerides

    Time frame: Baseline vs. within 1 week after intervention

  6. Changes in blood metabolite profiles by liquid chromatography / mass spectrometry

    Untargeted metabolomics analysis of plasma samples using liquid chromatography-mass spectrometry (LC/MS). Data will be reported as relative ion intensity changes from baseline (log2 fold change, mean ± SD) for significantly altered features.

    Time frame: Baseline vs. within 1 week after intervention

  7. Changes in body mass index (BMI)

    To observe changes in anthropometric measures. Measurement of height in meters and weight in kilograms to calculate body mass index (BMI = weight/height\^2) in kg/m\^2

    Time frame: Baseline vs. within 1 week after intervention

  8. Changes in waist to hip ratio (WHR)

    To observe changes in anthropometric measures. Measurement of waist circumference and hip circumference to calculate waist-to-hip-ratio WHR (waist circumference divided by hip circumference).

    Time frame: Baseline vs. within 1 week after intervention

  9. Changes in body fat percentage

    Measured by Bioelectrical Impedance Analysis (BIA)

    Time frame: Baseline vs. within 1 week after intervention

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Witkowski M, Wilcox J, Province V, Wang Z, Nemet I, Tang WHW, Hazen SL. Ingestion of the Non-Nutritive Sweetener Erythritol, but Not Glucose, Enhances Platelet Reactivity and Thrombosis Potential in Healthy Volunteers-Brief Report. Arterioscler Thromb Vasc Biol. 2024 Sep;44(9):2136-2141. doi: 10.1161/ATVBAHA.124.321019. Epub 2024 Aug 8. PubMed 39114916 ↗
  • Suez J, Cohen Y, Valdes-Mas R, Mor U, Dori-Bachash M, Federici S, Zmora N, Leshem A, Heinemann M, Linevsky R, Zur M, Ben-Zeev Brik R, Bukimer A, Eliyahu-Miller S, Metz A, Fischbein R, Sharov O, Malitsky S, Itkin M, Stettner N, Harmelin A, Shapiro H, Stein-Thoeringer CK, Segal E, Elinav E. Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance. Cell. 2022 Sep 1;185(18):3307-3328.e19. doi: 10.1016/j.cell.2022.07.016. Epub 2022 Aug 19. PubMed 35987213 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Nov 2026, 9 months later.

Of 379 non-industry interventional studies with no phase under Prediabetic State, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's planned 9 months is below that.

Counting every sponsor, half of 425 studies reached it within 23 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Jan 29, 2026
StartEst.
Jan 5, 2026
Primary completionEst.
Nov 1, 2026
CompletionEst.
Nov 1, 2026
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07377097
Responsible party
Marco Witkowski (Marco Witkowski, MD, PhD, Charite University, Berlin, Germany) — Principal investigator
First posted
Jan 29, 2026
Start date
Jan 5, 2026 (estimated)
Primary completion
Nov 1, 2026 (estimated)
Completion
Nov 1, 2026 (estimated)
Last update
Jan 29, 2026

Study contacts

Marco Witkowski, MD, PhD
Contact
fs-cpc@charite.de
+49 (0)30 450543775

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Saccharin · Trichlorosucrose · Erythritol

Start the discussion